Letters

Restoring natural capital As scientists and practitioners committed to ecological restoration, we found the analogy you made in your April issue1 between restoring natural capital (RNC)2 and new forms of cancer treatment3 to be an extremely powerful one. To a certain degree, RNC and ecological restoration in general, are indeed related to ecosystem degradation in the way that tumor ecology-based treatments are related to traditional cancer therapies, e.g., combined

| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

As scientists and practitioners committed to ecological restoration, we found the analogy you made in your April issue1 between restoring natural capital (RNC)2 and new forms of cancer treatment3 to be an extremely powerful one. To a certain degree, RNC and ecological restoration in general, are indeed related to ecosystem degradation in the way that tumor ecology-based treatments are related to traditional cancer therapies, e.g., combined radiation and chemotherapy.

What is clearly common to both approaches is that ecological restoration and cancer therapy are optimistic interventions with multiple payoffs to individuals and societies.4 Like cancer therapy, however, RNC is expensive. It is also time- and energy-consuming, and requires sustained commitment of the highest order. It is risky; there is no sure outcome in any given case, as your sidebar on South Africa's Working for Water program demonstrated.

Both RNC and cancer therapy are processes that assist the host to recover ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies